



Oncology Pharmacy Education Network (OPEN) Pre-Conference Wednesday, October 18, 2017

8:00 AM – 1:00 PM	<p>Registration</p>
8:00 – 8:30 AM	<p>Pre-Conference Breakfast</p>
8:30 – 8:45 AM	<p>Introductions and Welcome Steven D’Amato, BScPharm, <i>New England Cancer Specialists</i> Ali McBride, PharmD, MS, BCPS, BCOP, <i>The University of Arizona Cancer Center</i></p>
8:45 – 9:45 AM	<p>Between \$800,000 and \$800 Million: The True Cost of USP <800> Compliance James A. Jorgenson, MS, RPh, FASHP, <i>Visante Inc</i></p> <p>Learn practical approaches for USP <800> compliance by reviewing the facilities and engineering controls requirements of the updated USP Chapter <800> Hazardous Drugs-Handling in Healthcare Settings. Gain an understanding of the minimum requirements for receipt, storage, and compounding, as well as review real-life construction plans and the costs associated with them.</p>
9:45 – 10:45 AM	<p>Strategic Planning for the Oncology Pharmacy Steven D’Amato, BScPharm, <i>New England Cancer Specialists</i> Ali McBride, PharmD, MS, BCPS, BCOP, <i>The University of Arizona Cancer Center</i> Olalekan Ajayi, PharmD, <i>Welch Cancer Center</i></p> <p>Suggestions on where to focus your budget in 2018, including new technology and hardware, staffing and consultants.</p>
10:45 – 11:00 AM	<p>Refreshments and Networking Break</p>
11:00 – 11:45 PM	<p>Managing Oral Oncolytics: Pharmacists and Hospitals M. Jay Brown, PharmD, BCOP, <i>Novant Health</i></p> <p>Gain insight into how one comprehensive, collaborative, pharmacist-led oral chemotherapy program led to positive clinical and economic outcomes for both cancer patients and the institution.</p>
11:45 AM – 12:45 PM	<p>Networking Lunch</p>

12:45 – 1:45 PM

Non-Small Cell Lung Cancer Focus Session

Val R. Adams, PharmD, FCCP, BCOP, *Markey Cancer Center at the University of Kentucky*
Sandra Cuellar Puri, PharmD, BCOP, *University of Illinois Hospital & Health Sciences System*

Hear clinical case scenarios with evidence-based rationales for the optimal management of NSCLC. The discussion will cover biomarker testing, treatment options for patients who have developed resistance to first-line targeted therapies, and the recent advances in immunotherapies.

This session is supported by an educational grant from AstraZeneca.

1:45 – 4:15 PM

The Future of Part B Drug Reimbursement—What You Need to Know

Matt Sturm, MBA, *ECG Management Consultants, Inc*
Steven Taylor, *Oregon Oncology Specialists*

Over the last 18 months, the Center for Medicare & Medicaid Services (CMS) has announced several proposals to dramatically alter reimbursement for Part B drugs, including steep cuts for hospitals participating in 340B. While the outcome of these efforts is uncertain, commercial payors typically follow Medicare's lead when it comes to payment innovation.

Explore the underlying forces leading to changes in the Part B drug reimbursement policy, current and potential proposals to address the issue, and strategies that oncology programs may begin adapting to prepare for the impending changes.

The second half of the session will review case studies of practices which have responded to this changing economic landscape, and strategies that ACCC members are adopting to improve financial performance. Participants are welcome to share highlights from their program's recent successes.

This session includes a Refreshments and Networking Break from 2:45 – 3:15 PM.

Agenda subject to change.